| |
|
|
| |
| 投稿时间： 2015-04-21 最后修改时间： 2015-05-19 摘要点击次数: 2894 全文下载次数: 1365 |
| |
| 引用本文：郭志刚,管晓东,王宝敏,等.中国基本药物集中采购经济技术标评价指标构成分析[J].中国卫生政策研究,2015,8(6):27-33 |
|
| 郭志刚1 |
1. 北京大学药学院 北京 100191;
2. 北京大学医药管理国际研究中心 北京 100191;
3. 北京市卫生和计划生育委员会 北京 100053 |
| 基金项目:国家自然科学基金青年科学基金项目(71303011) |
| |
|
| | 摘要:目的:为完善我国基本药物经济技术标评审体系及招标采购工作提供建议。方法:检索搜集各省基本药物集中招标采购最新相关文件,对文件中经济技术标评审内容进行统计,结合实地调研和访谈,采用文献分析和对比分析方法进行研究。结果:基本药物质量层次划分较随意,经济技术标设置集中度不高、相同指标分值差异大、度量内容不统一、指标结构难以体现药品质量,质量类型指标缺乏区分度,政府存在不合理干预竞争行为。结论与建议:应尽量简化质量层次划分的指标类型和层次数,规范和科学设置各指标作用、内容、分值、权重和结构,提高评价药品质量的效能,完善政府与市场的作用。 | |
|
|
关键词:基本药物 经济技术标 集中招标采购 “双信封”招标
|
| |
| Structure of economic and technical indicator in centralized bidding procurement of essential medicines in China |
| GUO Zhi-gang1 |
1. School of Pharmaceutical Sciences, Peking University, Beijing 100191, China;
2. International Research Center of Medicinal Administration, Peking University, Beijing 100191, China;
3. Beijing Municipal Commission of Health and Family Planning, Beijing 100053, China |
| |
|
| | Abstract:Objective: To improve the economic and technical indicator's evaluation system and the essential medicines' centralized bidding procurement practice in China. Methods: By using the literature analysis, comparative analysis and field survey, we collected and analyzed the implementation plans and regulations for the essential medicines' centralized bidding procurement in 30 provinces. Results: The quality level classification lacks in precision. The economic and technical indicator's concentration grade is low, the score and content in each indicator unreasonably fluctuates in different provinces and these indicators are of low efficiency in bond with their structures for the drug quality evaluation. The quality level indicator lacks in the distinction degree and the government's unreasonable interference exists in competition. Conclusions and suggestions: The quality levels' indicator type and number should be simplified. The economic and technical indicators' function, content, score, weight value and the structure should be normatively and scientifically set to improve the efficiency during the drug quality evaluation and the government should strive to play their role in the market. | |
|
|
|
|
